NDAINTRAUTERINESYSTEM
Approved
Feb 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
LILETTA (levonorgestrel) by Blueprint Medicines is demonstrated. Approved for contraception, menorrhagia. First approved in 2015.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LILETTA is a levonorgestrel-releasing intrauterine system (IUS) approved in 2015 for contraception and menorrhagia management. It prevents pregnancy through multiple mechanisms including cervical mucus thickening, sperm immobilization, and endometrial alteration. The device is indicated for 13+ conditions ranging from dysmenorrhea to breast cancer management.
$0.028BPart D
Peak14.3 years to LOELow Part D penetration ($28K in 2023 with only 32 claims) suggests limited Medicare uptake; intrauterine device distribution primarily through commercial and specialty channels, likely a focused commercial team.
Mechanism of Action
demonstrated. Studies of LNG-releasing IUSs suggest several mechanisms for pregnancy prevention: prevention of fertilization due to the thickening of the cervical mucus, which inhibits sperm passage through the cervix, and inhibition of sperm mobility and function (capacitation), and alteration of…
Pharmacologic Class:
Progestin
Indications (2)
Worked on LILETTA at Blueprint Medicines? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.